about
Improvements in the early death rate among 9380 patients with acute myeloid leukemia after initial therapy: A SEER database analysisOral Azacitidine (CC-486) for the Treatment of Myelodysplastic Syndromes and Acute Myeloid LeukemiaTargeting acute myeloid leukemia with TP53-independent vosaroxin.Decitabine: a review of its use in older patients with acute myeloid leukaemia.REVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated acute myeloid leukaemia.Clinical characteristics and treatment outcome of acute myeloid leukemia in elderly patients in Korea: a retrospective analysisThioredoxin-1 inhibitor PX-12 induces human acute myeloid leukemia cell apoptosis and enhances the sensitivity of cells to arsenic trioxideCytotoxic effects of tetracycline analogues (doxycycline, minocycline and COL-3) in acute myeloid leukemia HL-60 cellsManagement of older or unfit patients with acute myeloid leukemiaAging-associated changes in hematopoiesis and leukemogenesis: what's the connection?Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome.Arginine dependence of acute myeloid leukemia blast proliferation: a novel therapeutic target.High dose cytarabine, mitoxantrone and l-asparaginase (HAMA) salvage for relapsed or refractory acute myeloid leukemia (AML) in the elderly.Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study.Value of Different Comorbidity Indices for Predicting Outcome in Patients with Acute Myeloid LeukemiaInhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia.Azacitidine might be beneficial in a subgroup of older AML patients compared to intensive chemotherapy: a single centre retrospective study of 227 consecutive patients.Cancerous inhibitor of protein phosphatase 2A determines bortezomib-induced apoptosis in leukemia cells.Cytogenetic Profile of de novo Acute Myeloid Leukemia Patients in Malaysia.Physician's Attitude Towards Treatment of Older Patients and the Choice of TherapySequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia.The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia.The value of molecular stratification for CEBPA(DM) and NPM1(MUT) FLT3(WT) genotypes in older patients with acute myeloid leukaemiaHydroxyurea synergizes with valproic acid in wild-type p53 acute myeloid leukaemia.The combination of valproic acid, all-trans retinoic acid and low-dose cytarabine as disease-stabilizing treatment in acute myeloid leukemiaEGFR inhibitors exacerbate differentiation and cell cycle arrest induced by retinoic acid and vitamin D3 in acute myeloid leukemia cellsHistone deacetylases 1 and 2 cooperate in regulating BRCA1, CHK1, and RAD51 expression in acute myeloid leukemia cells.Acute leukaemia: making sense of a complex blood cancer.Acute myeloid leukemia in older adults.Conventional chemotherapy or hypomethylating agents for older patients with acute myeloid leukaemia?Profile of sapacitabine: potential for the treatment of newly diagnosed acute myeloid leukemia in elderly patients.Heat shock protein 70 - the next chaperone to target in the treatment of human acute myelogenous leukemia?An extensive pharmacokinetic, metabolic and toxicological review of elderly patients under intensive chemotherapy for acute myeloid leukemia.Characterization of Purine-Rich Element Binding Protein B as a Novel Biomarker in Acute Myelogenous Leukemia Prognostication.Semi-Quantitative Mass Spectrometry in AML Cells Identifies New Non-Genomic Targets of the EZH2 Methyltransferase.Genomic and transcriptomic profiling of resistant CEM/ADR-5000 and sensitive CCRF-CEM leukaemia cells for unravelling the full complexity of multi-factorial multidrug resistanceEmerging strategies for the treatment of older patients with acute myeloid leukemia.Design of the randomized, Phase III, QUAZAR AML Maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemia.Preclinical and phase I results of decitabine in combination with midostaurin (PKC412) for newly diagnosed elderly or relapsed/refractory adult patients with acute myeloid leukemia.Parallel targeted next generation sequencing of childhood and adult acute myeloid leukemia patients reveals uniform genomic profile of the disease.
P2860
Q27336142-071E1171-D71D-429A-BC37-961668486A81Q28084813-4ECB2D9B-3E9B-476C-B6EA-29DF2C14FA15Q30245472-83063523-E738-4AD8-A664-0F31B5803562Q33407030-109BFE5B-3CF2-4B54-B3F4-5F28E78AC3B0Q33418735-86AB0314-CD96-4851-885C-CEE68E631AB9Q33875902-6FB934A5-B2FC-480A-861E-7E816833450CQ34121354-76561A0E-D095-46C6-9C0C-A934A1B79D23Q34703798-8ED4C427-44B4-4945-ACE2-11FEAE7C60CBQ34893307-348A91A2-8CEF-48F4-BAC5-219D62877C95Q35188247-E38E8ACB-F9D1-4297-B992-18BE280AA6F8Q35224437-369370A0-4CAB-4BCD-A227-DD55B092BDABQ35561304-68B95008-EDA8-44F7-B25E-56A28C5FEE50Q35988637-DE793DC4-E69E-420C-B798-DC4CF1FE712EQ36107268-E7F9BA3B-1484-4782-933C-4DCDE936FE8EQ36161529-E9480042-F088-45F6-B425-1EE99E2E90FDQ36515569-E73F0C7E-BA0B-4581-BFAB-540BD64E6083Q36805563-9AD46C3A-1AFB-4CDA-8839-72B8FE279D1CQ36805842-465DB60F-723A-43CD-B449-81AECF250376Q36816570-460CF64F-4D8B-449A-8561-5E5E223EF0FBQ36826175-48B32601-040A-485D-A69E-5F8B712664F3Q36862505-56C99A81-63FC-4107-8769-76E5B7C9A5B1Q36865880-31ACB731-0C00-4628-9112-6C66361E0DD1Q36866323-00792A57-6C1A-4D65-8414-261560510E1AQ36946725-DD5D7E43-3D09-49D7-9080-31A0FE138E51Q37153361-9A205055-40A8-40BC-894C-5078CCCCE27EQ37420045-89DF9794-74B0-4245-B1EA-51CF2EFE3F33Q37701599-A33EED5C-5C13-4593-BD8F-B3189B257A9DQ37981504-C8B004BC-74F1-4AC0-B0A1-25E24886FC0CQ38026008-A65DF8F4-91F5-4719-BF94-CFB0D1792652Q38091393-D267B024-D2B8-4DB2-AB03-15B6B34AB39FQ38213704-6242FF67-D109-4050-8FE9-C52235771DD6Q38222563-8AF1A3BA-1E8E-42E3-874B-D7795C1752FBQ38285621-B903C1E6-E791-4916-83EA-9AE099A2A678Q38638098-54503044-6581-471B-B381-4952BA058754Q38698037-C9682F4A-F804-4E45-B439-BC8194CED640Q38797514-8616407A-5EFF-4CF9-AA47-54B2ED78EAE2Q38818726-18B30451-1B20-4DAC-A2F3-D90F58C15858Q38918850-7623C3DE-4C05-4519-9D9E-05F8487CD215Q39135512-65C52DAB-354F-48CA-ACB0-7C8D81D84BD9Q39558408-B9AEC016-060D-4730-B5C0-A0F1234A9A4E
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Acute myeloid leukaemia in the elderly: a review.
@en
Acute myeloid leukaemia in the elderly: a review.
@nl
type
label
Acute myeloid leukaemia in the elderly: a review.
@en
Acute myeloid leukaemia in the elderly: a review.
@nl
prefLabel
Acute myeloid leukaemia in the elderly: a review.
@en
Acute myeloid leukaemia in the elderly: a review.
@nl
P2093
P2860
P1476
Acute myeloid leukaemia in the elderly: a review.
@en
P2093
Bruno C Medeiros
Daniel A Pollyea
Holbrook E Kohrt
P2860
P304
P356
10.1111/J.1365-2141.2010.08470.X
P407
P577
2011-03-01T00:00:00Z